Neuropsychiatric aspects of Alzheimer's disease: the cholinergic hypothesis revisited.
about
Maintenance treatment of depression in old age: a randomized, double-blind, placebo-controlled evaluation of the efficacy and safety of donepezil combined with antidepressant pharmacotherapySuccessful use of donepezil for the treatment of dementia with Lewy bodies.Increased striatal dopamine (D2/D3) receptor availability and delusions in Alzheimer disease.Cholinesterase inhibitors for the treatment of Alzheimer's disease in the elderly.Assessment and management of behavioral disturbances in Alzheimer disease.An open-label pilot study of acetylcholinesterase inhibitors to promote functional recovery in elderly cognitively impaired stroke patientsCholinergic therapy for neuropsychiatric symptoms in neurologic disorders.Pharmacotherapy of behavioral and psychological symptoms of dementia: time for a different paradigm?Association between the APOE genotype and psychopathologic symptoms in Alzheimer's diseaseNeuropsychiatric Symptoms, Endophenotypes, and Syndromes in Late-Onset Alzheimer's Disease: Focus on APOE Gene.Pharmacologic therapy of dementia with Lewy bodies.Symptoms of sleep disturbance in persons with Alzheimer's disease and normal elderlyIndependence of changes in behavior from cognition and function in community-dwelling persons with Alzheimer's disease: a factor analytic approach.Brain aging research at the close of the 20th century: from bench to bedside.GABAergic function in Alzheimer's disease: evidence for dysfunction and potential as a therapeutic target for the treatment of behavioural and psychological symptoms of dementia.Neuronal death in Alzheimer's disease and therapeutic opportunities.Acetylcholinesterase inhibition ameliorates deficits in motivational driveGalantamine: use in Alzheimer's disease and related disorders.Intraperitoneal Administration of a Novel TAT-BDNF Peptide Ameliorates Cognitive Impairments via Modulating Multiple Pathways in Two Alzheimer's Rodent Models.Cognitive performance in patients with Alzheimer's disease receiving cholinesterase inhibitors for up to 5 years.Metrifonate (Trichlorfon): a review of the pharmacology, pharmacokinetics and clinical experience with a new acetylcholinesterase inhibitor for Alzheimer's disease.NMDA Neurotransmission Dysfunction in Behavioral and Psychological Symptoms of Alzheimer's Disease.Extracts and constituents of Leontopodium alpinum enhance cholinergic transmission: brain ACh increasing and memory improving properties.Comparative Study of White and Steamed Black Panax ginseng, P. quinquefolium, and P. notoginseng on Cholinesterase Inhibitory and Antioxidative Activity.Cholinergic modulation of the cerebral metabolic response to citalopram in Alzheimer's disease.Current therapeutic options for Alzheimer's diseaseImpact of cholinesterase inhibitors on behavioral and psychological symptoms of Alzheimer's disease: a meta-analysis.Donepezil delays progression to AD in MCI subjects with depressive symptoms.Drugs with anticholinergic properties: a potential risk factor for psychosis onset in Alzheimer's disease?Switching from oral cholinesterase inhibitors to the rivastigmine transdermal patch.Anticholinergics: theoretical and clinical overview.Examination and Estimation of Anticholinergic Burden: Current Trends and Implications for Future Research.The Effect of the Association between Donepezil and Choline Alphoscerate on Behavioral Disturbances in Alzheimer's Disease: Interim Results of the ASCOMALVA Trial.Antiamnesic Effects of Walnuts Consumption on Scopolamine-Induced Memory Impairments in RatsNeuropathological changes in the nucleus basalis in schizophrenia.Galantamine for the treatment of BPSD in Thai patients with possible Alzheimer's disease with or without cerebrovascular disease.Efficacy of metrifonate in improving the psychiatric and behavioral disturbances of patients with Alzheimer's disease.Rivastigmine in the treatment of parkinsonian psychosis and cognitive impairment: preliminary findings from an open trial.Neuropsychiatric differences between Parkinson's disease with dementia and Alzheimer's disease.Novel cognitive improving and neuroprotective activities of Polygala tenuifolia Willdenow extract, BT-11.
P2860
Q30432684-4A575367-ECE0-4ABD-A8ED-D389354A92ECQ32052939-29645DCA-AE52-459A-AF2F-19BDAE7923F2Q33636523-F514D77E-660B-4C1D-A032-7BBD13D7421FQ33885924-E639BFB6-85D1-4FBF-89E6-96D0A58E43A0Q34031223-B2C10F00-586A-4FB9-A1C4-025DED88EB5CQ34038332-C03624BB-C63A-42C9-8E35-320E456005BAQ34108192-CA43061C-911B-45C9-9A0A-FC4D90A7545AQ34146983-B34E0258-F523-4227-B563-4A7C1ADB3FE2Q34530796-CEF98FA7-2815-4AB6-912A-06F51AF34909Q34953672-51AEF119-7C3E-4398-99F8-C4AA4CBE98DAQ35029479-FBD0D79C-F24B-4021-96D7-3A3C6B7FB51EQ35211973-57B04A14-8B41-4CEA-8D01-BFEDEB1D6A85Q35226430-DA5D655C-88DE-4AE1-B921-5142AA691340Q35236407-C9C1551C-8CDF-4486-846B-92FF269966C7Q35884948-2936C95E-C2C9-4580-8E64-49C42A8708FEQ35889067-8AC6508B-8B01-4928-B7C6-3B732BE4869BQ35893873-BCB97306-99D1-4E5D-AF88-E489F8D05C10Q36107053-F4636E5D-3E62-4333-8266-874655DC3445Q36158803-3C4897F5-0D7A-47B8-8A48-BB920625F63BQ36166433-264F96C9-161A-416E-819B-52ACDAEBB3FDQ36181304-F173A1B0-6052-4BA8-95D2-DDBA02925502Q36310524-7EBCCEBC-88A3-49EF-8F22-1A958A10ABB8Q36477185-172C3430-F71C-4124-B653-FB5545FC751EQ36861025-C117A091-9FF5-43C3-9397-8130F5B28199Q37092481-1E957492-8194-4DBB-AD49-1A992A336CE8Q37108146-82108951-D6D6-40C1-8D06-911F68DCA673Q37193026-905EA837-9078-489C-B84F-923358F317E8Q37231378-16598260-5A32-483D-8C02-06D93F5F159AQ37529854-F6A1C9BA-8F35-492D-B744-E85911C9B7E9Q37673376-FE18BE9F-91FE-4B90-81A1-DAAC6CCAC636Q38769800-29966E73-8BDB-43B9-AE51-7B70F8776B7DQ38886942-E42C2F86-24B9-43BA-B78E-49B17204F10BQ39051115-E71E7730-C768-484C-9CF5-B8569F3CD128Q41835947-B4284DFE-CF0D-4071-BD09-E3FED2AEC9C7Q42517769-4391506E-2509-4696-80ED-667B0A4ED7E5Q42599830-C8BF37DC-DD2E-4E2B-85F3-694929C43193Q43648552-A721C0C9-A0AA-4B4C-AABC-13A5B482312FQ43827133-35209652-169C-442A-BAEC-2CA13C3248A5Q44063087-6B83283E-4FF9-4ECD-AEEC-8A1B81A71B22Q44188020-147FB698-BF6E-44CA-8126-9C969AA5C9E7
P2860
Neuropsychiatric aspects of Alzheimer's disease: the cholinergic hypothesis revisited.
description
1996 nî lūn-bûn
@nan
1996年の論文
@ja
1996年論文
@yue
1996年論文
@zh-hant
1996年論文
@zh-hk
1996年論文
@zh-mo
1996年論文
@zh-tw
1996年论文
@wuu
1996年论文
@zh
1996年论文
@zh-cn
name
Neuropsychiatric aspects of Alzheimer's disease: the cholinergic hypothesis revisited.
@en
type
label
Neuropsychiatric aspects of Alzheimer's disease: the cholinergic hypothesis revisited.
@en
prefLabel
Neuropsychiatric aspects of Alzheimer's disease: the cholinergic hypothesis revisited.
@en
P356
P1433
P1476
Neuropsychiatric aspects of Alzheimer's disease: the cholinergic hypothesis revisited.
@en
P2093
P304
P356
10.1212/WNL.47.4.876
P407
P577
1996-10-01T00:00:00Z